ABCC1 and glioma: miR-9-5p decreased in glioma patients, and by restoring the content of miR-9-5p, ABCC1 could be inhibited to promote the sensitivity of TMZ-resistant glioma cells to TMZ, which may be a potential therapeutic target in clinic.